Analyst Reco. Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
34.44 ^USD	+4.76%		+9.23%	+6.03%

Jun. 04	Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating	MT
May. 28	Sector Update: Health Care Stocks Retreat Tuesday Afternoon	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating	Jun. 04	MT
Corcept Therapeutics Insider Sold Shares Worth $1,400,000, According to a Recent SEC Filing	May. 16	MT
Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating	May. 02	MT
Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing	Mar. 21	MT
Truist Securities Adjusts Price Target on Corcept Therapeutics to $42 From $36, Maintains Buy Rating	Feb. 16	MT
HC Wainwright Adjusts Corcept Therapeutics' Price Target to $28 From $34, Keeps Buy Rating	Jan. 02	MT
Canaccord Genuity Adjusts Corcept Therapeutics' Price Target to $38 From $37, Keeps Buy Rating	Dec. 13	MT
Truist Upgrades Corcept Therapeutics to Buy Rating From Hold, Adjusts Price Target to $38 From $29	Nov. 06	MT
HC Wainwright Adjusts Price Target on Corcept Therapeutics to $34 From $32, Keeps Buy Rating	Nov. 02	MT
Canaccord Genuity Adjusts Price Target on Corcept Therapeutics to $35 From $34, Maintains Buy Rating	23-08-25	MT
Truist Securities Adjusts Price Target on Corcept Therapeutics to $29 From $26, Maintains Hold Rating	23-08-03	MT
HC Wainwright Adjusts Price Target on Corcept Therapeutics to $32 From $30, Maintains Buy Rating	23-08-03	MT
Truist Securities Adjusts Price Target on Corcept Therapeutics to $26 From $28, Maintains Hold Rating	23-05-26	MT
SVB Securities Initiates Corcept Therapeutics at Market Perform With $25 Price Target	23-04-11	MT
Piper Sandler Starts Corcept Therapeutics at Overweight With $27 Price Target	23-04-04	MT
Canaccord Genuity Adjusts Price Target on Corcept Therapeutics to $32 From $33, Maintains Buy Rating	23-03-08	MT
Jefferies Downgrades Corcept Therapeutics to Hold From Buy, Adjusts Price Target to $22 From $35	23-02-15	MT
HC Wainwright Cuts Price Target on Corcept Therapeutics to $30 From $33, Reiterates Buy Rating	22-12-09	MT
HC Wainwright Adjusts Price Target on Corcept Therapeutics to $33 From $29, Reiterates Buy Rating	22-08-04	MT
Truist Securities Downgrades Corcept Therapeutics to Hold From Buy; Price Target is $30	22-08-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Analyst Reco.

Filters